Browsing Tag
Somfit D
1 post
Compumedics (ASX: CMP) surges as FY27 growth replaces guidance doubt
Compumedics missed revised FY26 guidance, yet recurring revenue jumped 70%. Can Somfit D and MEG delivery turn ASX: CMP into an FY27 rerating?